At OncoTEX Inc., we’re on a mission to treat cancer effectively, without the prohibitive side effects we know today.
We are addressing an urgent major unmet clinical need by transforming cancer therapy with TEX Core, an oncology drug platform that can create a new suite of life-changing cancer therapeutics.
OncoTEX Inc. is a proud member of The iQ Group Global, a consortium of companies who work together to find, fund and develop bioscience discoveries to create life-changing medical innovations..
A world first platform, TEX Core conjugates with oncology therapies to create novel oncology compounds that are delivered directly to tumor cells, with minimal side effects.
TEX Core-developed compounds are designed to be tumor localizing, well-tolerated, MRI-detectable and efficacious in multiple solid tumors, including cancer cells that fail to respond to current therapies.
OXALITEX: THE FIRST TEX CORE COMPOUND
The first TEX Core oncology compound to be developed is OxaliTEX, which localizes to solid tumors including ovarian, lung and colorectal cancers.
OxaliTEX activates within cancer cells, overcoming multiple mechanisms of resistance and minimizing toxic side effects. The lead indication for OxaliTEX is ovarian cancer, the number one cause of gynecological cancer deaths globally.